Article
p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma.
Cancer - 15 Aug 2000
King T C, Akerley W, Fan A C, Moore T, Mangray S, Hsiu Chen M, Safran H
Abstract excerpt
BACKGROUND: In vitro data and animal studies suggest that paclitaxel may have a unique ability to activate tumor cell apoptosis in the absence of wild-type p53 function. The authors previously demonstrated that response to paclitaxel and concurrent radiation was not affected by p53 mutations in nonsmall cell lung carcinoma (NSCLC). We sought to determine whether p53 mutations affect response to paclitaxel alone...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.